Back to Results

Genomma Lab Internacional SAB De CV (GNMLF)

Featured in Small-Cap Stocks

Genomma Lab Internacional, S.A.B. de C.V. is a Mexico-based healthcare company incorporated in 1996 and listed on OTC Markets as common stock. Through itself and its subsidiaries, the company develops, sells, and markets branded pharmaceutical and personal care products in Mexico and international markets. Its portfolio spans a broad range of consumer health categories, including anti-acne and antibacterial products, shampoos and scalp-care items, skin treatments, pain-relief ointments, anti-fungal and digestive relief products, anti-wrinkle and antacid treatments, and other medicines and care products. The company is headquartered in Mexico City, Mexico.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-GNML.F
$1.20
40.0% Upside
Undervalued
—
—
—
Good
—
—
—
0.0%
July 22, 2026
9.0x
1.2x
0.8x
826.3 M
1.111 B
36.1%
69.0%
9.0
48.8%
88.5%
Send a message
Valuation • Fair Value

Genomma Lab Internacional SAB De CV (OTC-GNML.F) Fair Value by Valuation Model

Compare the primary fair value estimate for Genomma Lab Internacional SAB De CV (OTC-GNML.F) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.20

Estimated upside of 40.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.51

Discounted cash flow valuation reference.

Ben Graham Formula Value

$1.05

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.10

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Genomma Lab Internacional SAB De CV (OTC-GNML.F) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Genomma Lab Internacional SAB De CV (OTC-GNML.F)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

966.7 M

Current operating scale indicator.

Revenue Forecast

1.036 B

Forward revenue estimate.

EBITDA

225.8 M

Current operating profitability reference.

EBITDA Forecast

240.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Genomma Lab Internacional SAB De CV (OTC-GNML.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Genomma Lab Internacional SAB De CV (OTC-GNML.F)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.62

No elevated caution signal from this screen.

Altman Z-Score

9.0

Relatively strong balance-sheet zone.

FCF / Net Income

88.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Genomma Lab Internacional SAB De CV (OTC-GNML.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Genomma Lab Internacional SAB De CV (OTC-GNML.F)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 22, 2026

Days to Earnings

1

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

48.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Genomma Lab Internacional SAB De CV (OTC-GNML.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Genomma Lab Internacional SAB De CV (OTC-GNML.F) Stock Forecast & Technical Outlook

Review Genomma Lab Internacional SAB De CV (OTC-GNML.F) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Genomma Lab Internacional SAB De CV (OTC-GNML.F)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Genomma Lab Internacional SAB De CV (OTC-GNML.F) Stock FAQ

Quick answers about Genomma Lab Internacional SAB De CV (OTC-GNML.F) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.20
Estimated upside 40.0%
Valuation Rating
Undervalued
Estimated upside of 40.0%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Good
Current financial-health read

The current fair value estimate for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is $1.20. This implies an estimated upside of 40.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 40.0% versus the current market price.

An analyst price target for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is not currently available in the latest data file.

The current financial health read for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is July 22, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Genomma Lab Internacional SAB De CV (OTC-GNML.F) is 9.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Genomma Lab Internacional SAB De CV is 826.3 M.

The current enterprise value listed for Genomma Lab Internacional SAB De CV is 1.111 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Genomma Lab Internacional SAB De CV is OTC-GNML.F, and the stock is listed on OTC Markets.

Genomma Lab Internacional SAB De CV (OTC-GNML.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Genomma Lab Internacional SAB De CV is 36.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Genomma Lab Internacional SAB De CV is 69.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)